Ying Chen

22.0k total citations · 3 hit papers
615 papers, 16.5k citations indexed

About

Ying Chen is a scholar working on Molecular Biology, Cancer Research and Pharmacology. According to data from OpenAlex, Ying Chen has authored 615 papers receiving a total of 16.5k indexed citations (citations by other indexed papers that have themselves been cited), including 286 papers in Molecular Biology, 85 papers in Cancer Research and 82 papers in Pharmacology. Recurrent topics in Ying Chen's work include Peroxisome Proliferator-Activated Receptors (25 papers), Autophagy in Disease and Therapy (23 papers) and MicroRNA in disease regulation (22 papers). Ying Chen is often cited by papers focused on Peroxisome Proliferator-Activated Receptors (25 papers), Autophagy in Disease and Therapy (23 papers) and MicroRNA in disease regulation (22 papers). Ying Chen collaborates with scholars based in China, United States and Taiwan. Ying Chen's co-authors include Joachim Herz, Vasilis Vasiliou, David C. Thompson, Jian‐xing Ma, Timothy P. Dalton, Vindhya Koppaka, Yang Hu, Daniel W. Nebert, Howard G. Shertzer and Scott N. Schneider and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Ying Chen

580 papers receiving 16.2k citations

Hit Papers

Aldehyde dehydrogenases i... 2012 2026 2016 2021 2012 2012 2022 100 200 300 400

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Ying Chen 7.7k 2.0k 1.6k 1.6k 1.5k 615 16.5k
Fang Wang 9.2k 1.2× 1.9k 0.9× 1.3k 0.8× 2.3k 1.4× 1.3k 0.9× 734 20.2k
Young‐Myeong Kim 7.7k 1.0× 1.6k 0.8× 1.2k 0.7× 3.0k 1.9× 1.1k 0.7× 358 16.4k
Akira Hara 6.7k 0.9× 1.6k 0.8× 2.1k 1.3× 1.0k 0.6× 1.0k 0.7× 786 16.0k
Peng Li 6.3k 0.8× 1.2k 0.6× 1.5k 0.9× 2.0k 1.2× 695 0.5× 548 17.4k
Dao Wen Wang 9.5k 1.2× 3.0k 1.5× 1.1k 0.7× 1.7k 1.0× 848 0.6× 605 21.3k
Edwin K. Jackson 5.8k 0.8× 1.4k 0.7× 2.2k 1.4× 2.4k 1.5× 1.4k 0.9× 502 19.4k
Pamela Maher 9.5k 1.2× 1.5k 0.7× 1.1k 0.7× 2.8k 1.7× 1.9k 1.3× 229 16.8k
Daniel K. Nomura 9.8k 1.3× 4.0k 1.9× 1.8k 1.1× 1.7k 1.0× 3.2k 2.2× 165 17.5k
Lisardo Boscá 5.6k 0.7× 1.8k 0.9× 893 0.5× 2.2k 1.4× 1.2k 0.8× 284 12.8k
Raymond C. Harris 8.6k 1.1× 1.3k 0.6× 1.8k 1.1× 2.5k 1.6× 3.1k 2.1× 334 22.5k

Countries citing papers authored by Ying Chen

Since Specialization
Citations

This map shows the geographic impact of Ying Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying Chen more than expected).

Fields of papers citing papers by Ying Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ying Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying Chen. The network helps show where Ying Chen may publish in the future.

Co-authorship network of co-authors of Ying Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Ying Chen. A scholar is included among the top collaborators of Ying Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ying Chen. Ying Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Ying, et al.. (2025). Mechanism of valproic acid-induced hepatic steatosis via enhancing NRF2-FATP2-mediated fatty acid uptake. Theranostics. 15(11). 5258–5276. 2 indexed citations
2.
3.
Jiang, Hongyan, Lulu Li, Xue Zhang, et al.. (2024). Novel insights into the association between genetically proxied inhibition of proprotein convertase subtilisin/kexin type 9 and risk of sarcopenia. Journal of Cachexia Sarcopenia and Muscle. 15(6). 2417–2425.
5.
Cao, Xia, Xiao Wang, Mengru Yang, et al.. (2024). Multi-metabolomics and intestine microbiome analysis: YZC extract ameliorates septic-ALI by modulating intestine microbiota to reduce TMAO/NLRP3 signaling. Phytomedicine. 130. 155345–155345. 5 indexed citations
6.
Lin, Yi‐Hsuan, et al.. (2024). GW4064 inhibits migration and invasion through cathepsin B and MMP2 downregulation in human bladder cancer. Chemico-Biological Interactions. 389. 110869–110869. 8 indexed citations
8.
Chen, Ying, et al.. (2023). In-vitro antibacterial activity and mechanism of Monarda didyma essential oils against Carbapenem-resistant Klebsiella pneumoniae. BMC Microbiology. 23(1). 263–263. 11 indexed citations
9.
He, Lei, Qian Hu, Jiukai Zhang, et al.. (2023). An integrated untargeted metabolomic approach reveals the quality characteristics of black soybeans from different geographical origins in China. Food Research International. 169. 112908–112908. 18 indexed citations
12.
Yang, Lingwei, Suozhen Hui, Liang Zhou, et al.. (2023). Genome-wide identification and expression analysis of 3-ketoacyl-CoA synthase gene family in rice (Oryza sativa L.) under cadmium stress. Frontiers in Plant Science. 14. 1222288–1222288. 11 indexed citations
13.
Chen, Ying, et al.. (2022). Systematic elucidation of the pharmacological mechanisms of Hedysarum Multijugum Maxim for treating rhinitis via network. Phytomedicine Plus. 2(4). 100341–100341. 1 indexed citations
14.
Gopal, Ajay K., Ronald Levy, Roch Houot, et al.. (2020). First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. Clinical Cancer Research. 26(11). 2524–2534. 45 indexed citations
15.
Zheng, Bixia, Qiuxia Chen, Chunli Wang, et al.. (2019). Whole‐genome sequencing revealed an interstitial deletion encompassing OCRL and SMARCA1 gene in a patient with Lowe syndrome. Molecular Genetics & Genomic Medicine. 7(9). e876–e876. 8 indexed citations
16.
Shan, Nan, Xiaoqiu Xiao, Ying Chen, et al.. (2015). Expression of DAB2IP in human trophoblast and its role in trophoblast invasion. The Journal of Maternal-Fetal & Neonatal Medicine. 29(3). 393–399. 8 indexed citations
17.
Wei, Jing, Ying Chen, Lei Lü, et al.. (2014). Human Umbilical Cord Blood–Derived Mesenchymal Stem Cells Producing IL15 Eradicate Established Pancreatic Tumor in Syngeneic Mice. Molecular Cancer Therapeutics. 13(8). 2127–2137. 61 indexed citations
18.
Chen, Ying, Hua Hao, Songqing He, et al.. (2010). Lipoxin A4 and Its Analogue Suppress the Tumor Growth of Transplanted H22 in Mice: The Role of Antiangiogenesis. Molecular Cancer Therapeutics. 9(8). 2164–2174. 84 indexed citations
19.
Costa, Bruno M., Justin S. Smith, Ying Chen, et al.. (2010). Reversing HOXA9 Oncogene Activation by PI3K Inhibition: Epigenetic Mechanism and Prognostic Significance in Human Glioblastoma. Cancer Research. 70(2). 453–462. 122 indexed citations
20.
Yu, Guanzhen, Jiejun Wang, Ying Chen, et al.. (2009). Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer. Clinical Cancer Research. 15(5). 1821–1829. 135 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026